Oncternal Therapeutics, Inc. (ONCT)
Dec 3, 2024 - ONCT trading suspended
0.527
-0.167 (-24.12%)
Inactive · Last trade price
on Dec 2, 2024
Oncternal Therapeutics Revenue
Oncternal Therapeutics had revenue of $494.00K in the quarter ending September 30, 2024, with 175.98% growth. This brings the company's revenue in the last twelve months to $2.16M, up 227.92% year-over-year. In the year 2023, Oncternal Therapeutics had annual revenue of $785.00K, down -47.32%.
Revenue (ttm)
$2.16M
Revenue Growth
+227.92%
P/S Ratio
0.72
Revenue / Employee
$72,033
Employees
30
Market Cap
1.56M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionONCT News
- 5 months ago - Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations - GlobeNewsWire
- 9 months ago - Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC - GlobeNewsWire
- 1 year ago - Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results - GlobeNewsWire
- 1 year ago - Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results - GlobeNewsWire
- 1 year ago - Oncternal Therapeutics to Present in JonesTrading Healthcare Summit - GlobeNewsWire
- 1 year ago - Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 1 year ago - Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript - Seeking Alpha